产品名称
Iotrolan for system suitability, European Pharmacopoeia (EP) Reference Standard
SMILES string
Ic1c(c(c(c(c1C(=O)NC(C(O)CO)CO)I)C(=O)NC(C(O)CO)CO)I)N(C)C(=O)CC(=O)N(C)c2c(c(c(c(c2I)C(=O)NC(C(O)CO)CO)I)C(=O)NC(C(O)CO)CO)I
InChI
1S/C37H48I6N6O18/c1-48(32-28(40)22(34(64)44-12(4-50)16(58)8-54)26(38)23(29(32)41)35(65)45-13(5-51)17(59)9-55)20(62)3-21(63)49(2)33-30(42)24(36(66)46-14(6-52)18(60)10-56)27(39)25(31(33)43)37(67)47-15(7-53)19(61)11-57/h12-19,50-61H,3-11H2,1-2H3,(H,44,64)(H,45,65)(H,46,66)(H,47,67)
InChI key
XUHXFSYUBXNTHU-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
iotrolan
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
Application
Iotrolan for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
G Diederichs et al.
RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 179(10), 1061-1067 (2007-09-06)
Many patients dislike oral contrast media due to their bad taste. The aim of the present study was to identify a solution that tastes better while providing the same opacification in order to offer oncological patients an alternative to the
I Böhm et al.
RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 178(3), 306-312 (2006-03-02)
To survey contrast media (CM)-induced alterations of complement factors. In 31 adult patients, who received either an iotrolan (n = 19) or iopromide (n = 12) i. v. injection for CT examination, complement factors C1 q, C3, C4, C5 a
R Schmitt et al.
RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 175(7), 911-919 (2003-07-09)
In literature the diagnostic value of MRI for detecting lesions of the carpal ligaments and the TFCC is judged controversially. The aim of the following study is to determine the diagnostic accuracy of direct MR arthrography for depicting and staging
Hans H Schild et al.
Radiology, 240(1), 56-64 (2006-05-25)
To prospectively evaluate adverse events (AEs) in patients who underwent nonionic monomeric or dimeric contrast media-enhanced computed tomography (CT) and to compare these effects with AEs in patients who underwent unenhanced CT. Local ethics committee approval and written informed consent
Andreas Bender et al.
Neurology, 63(7), 1311-1313 (2004-10-13)
Symptomatic aseptic, chemical meningitis is a rare complication of myelography. Its acute clinical course and standard laboratory findings are indistinguishable from those of bacterial meningitis. The authors present a case of severe postmyelographic chemical meningitis and compare CSF and serum
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持